Abstract 510P
Background
Maintenance therapy is one strategy that has been investigated as a way of improving outcomes in patients with non-small cell lung cancer. This study was conducted to evaluate the effect of weekly paclitaxel as a continuation maintenance therapy in advanced NSCLC patients.
Methods
This prospective study included patients with advanced non-small cell lung cancer (NSCLC) patients with stage IIIB (T4 N2 or any T N3 disease) and Stage IV disease (T any N M1) with performance status (P.S) ≤ 2 who presented to Clinical Oncology Department in Menoufia University. All patients received carboplatin – paclitaxel for 4 cycles. the patients with initial good response, or stable disease were randomized into 2 arms, the first arm, received weekly paclitaxel (70 mg/m2) as continuation maintenance therapy for 3 weeks of 4 weeks cycle, and evaluated every 12 weeks, continued till disease progression or unacceptable toxicity (maintenance arm), and the second arm was kept under observation (observation arm). The Primary end-point was time to progression, and the Secondary end-point was toxicity of the drug, and the quality of life of the patients, and overall survival.
Results
Total 92 patients were included, 46 patients were in the maintenance arm, and 46 patients were in the observation arm. only 14 patients continued maintenance paclitaxel till end of the study (30.4%). Most patients who completed paclitaxel maintenance therapy till the end of follow up period was 0 PS (85.7%), stage IIIB (57.1%), grade II (42.9%), and all of them was adenocarcinoma. Treatment related toxicities were significantly higher in the maintenance arm compared to observation arm p value: (0.017, 0.001 and <0.001) respectively. lung cancer symptoms scale was bettre in maintenance arm. PFS for maintenance arm was 10 months, while 8 months for observation arm (P value =0.16). OS in maintenance arm was 29 months versus 12.5 months for observation arm with significant P value (0.047).
Conclusions
continuation Maintenance with paclitaxel can be a reasonable treatment option in patients with NSCLC with performance status 0, stage IIIB, grade II tumors of adenocarcinoma histology who experienced complete or partial response after initial paclitaxel carboplatin combination.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract